Physician profile
Peter L Seraphin
NPI 1831204734
$5,105.51
in general payments reported to CMS, 2019-2025
38 companies · $763 in 2025
The $763 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $173 · 2021: $820 · 2022: $902 · 2023: $777 · 2024: $510 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,143.85 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $742.52 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $703.55 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $403.52 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $396.04 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $285.82 | 2019-2025 | |
| Ardelyx, INC. | $138.17 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $110.06 | 2022-2024 | |
| Celgene Corporation | $104.84 | 2021-2024 | Zeposia |
| Shire North American Group INC | $89.66 | 2019 | |
| Qol Medical, LLC | $76.60 | 2019-2023 | Sucraid |
| Evoke Pharma, INC. | $73.07 | 2021-2023 | Gimoti |
| Merck Sharp & Dohme LLC | $70.40 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $63.44 | 2022-2024 | Talicia |
| Intercept Pharmaceuticals, INC. | $62.76 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $61.48 | 2021-2022 | |
| Lilly USA, LLC | $50.63 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $48.83 | 2023 | Clenpiq, Rebyota |
| Allergan, INC. | $47.99 | 2019 | |
| Vivus LLC | $39.10 | 2023-2025 | Pancreaze |
| Pentax of America, INC. | $36.48 | 2022 | |
| Ironwood Pharmaceuticals, INC | $34.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.14 | 2023 | |
| Madrigal Pharmaceuticals | $26.81 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $26.17 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $25.82 | 2025 | Zenpep |
| Celltrion USA INC. | $22.67 | 2025 | Vegzelma |
| Mirum Pharmaceuticals, INC. | $22.13 | 2025 | Livmarli |
| Alfasigma USA, INC. | $22.02 | 2020 | |
| Nestle Healthcare Nutrition INC. | $21.71 | 2022 | |
| Organon LLC | $19.84 | 2022 | |
| Sandoz INC. | $19.52 | 2024 | Hyrimoz |
| Ucb, INC. | $18.92 | 2019 | |
| Daiichi Sankyo INC. | $18.47 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.02 | 2024 | Iqirvo |
| W. L. Gore & Associates, INC. | $16.53 | 2021 | |
| Exact Sciences Corporation | $16.14 | 2025 | Cologuard Collection Kit |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,882.69 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Seraphin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.